PuSH - Publikationsserver des Helmholtz Zentrums München

Tsiverioti, C.A.* ; Gottschlich, A.* ; Theurich, S.* ; Anders, H.J.* ; Kroiss, M.* ; Kobold, S. ; Trefny, M.P.*

Beyond CAR T cells: exploring alternative cell sources for CAR-like cellular therapies.

Biol. Chem., DOI: 10.1515/hsz-2023-0317 (2024)
Verlagsversion DOI PMC
Open Access Gold (Paid Option)
Creative Commons Lizenzvertrag
Chimeric antigen receptor (CAR)-T cell therapy has led to remarkable clinical outcomes in the treatment of hematological malignancies. However, challenges remain, such as limited infiltration into solid tumors, inadequate persistence, systemic toxicities, and manufacturing insufficiencies. The use of alternative cell sources for CAR-based therapies, such as natural killer cells (NK), macrophages (MΦ), invariant Natural Killer T (iNKT) cells, γδT cells, neutrophils, and induced pluripotent stem cells (iPSC), has emerged as a promising avenue. By harnessing these cells' inherent cytotoxic mechanisms and incorporating CAR technology, common CAR-T cell-related limitations can be effectively mitigated. We herein present an overview of the tumoricidal mechanisms, CAR designs, and manufacturing processes of CAR-NK cells, CAR-MΦ, CAR-iNKT cells, CAR-γδT cells, CAR-neutrophils, and iPSC-derived CAR-cells, outlining the advantages, limitations, and potential solutions of these therapeutic strategies.
Altmetric
Weitere Metriken?
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Korrespondenzautor
Schlagwörter Car-nk Cells ; Car-t Cells ; Car-inkt Cells ; Car-macrophages ; Car-neutrophils ; Car-γδt cells; Chimeric-antigen-receptor; Natural-killer-cells; Pluripotent Stem-cells; V-alpha-24-invariant Nkt Cells; Acute Myeloid-leukemia; In-vivo Expansion; Phase-i; Dendritic Cells; Adoptive Immunotherapy; Antitumor-activity
ISSN (print) / ISBN 1431-6730
e-ISSN 1437-4315
Zeitschrift Biological Chemistry
Verlag de Gruyter
Verlagsort Genthiner Strasse 13, D-10785 Berlin, Germany
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed
Institut(e) Unit for Clinical Pharmacology (KKG-EKLiP)
Förderungen Go-Bio-Initiative